SWOG clinical trial number
CTSU/E2810

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Closed
Phase
Abbreviated Title
Metastatic Renal Cell Post Metastatectomy, Pazopanib, Phase III
Activated
09/01/2012
Closed
07/25/2017
Participants
CTSU

Research committees

Genitourinary Cancer

Treatment

Pazopanib Placebo

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.

Publication Information Expand/Collapse

2019

Randomized, DoubleBlind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy: A Trial of the ECOG-ACRIN Cancer Research Group (E2810)

LJ Appleman;M Puligandla;SK Pal;W Harris;N Agarwal;B Addis Costello;CW Ryan;M Pins;JE Kolesar;DA Vaena;RA Parikh;M Hashmi;JP Dutcher;RS DiPaola;N Haas;M Carducci J Clin Oncol 37(suppl; abstr 4502); American Society of Clinical Oncology (5/31-6/4/19, Chicago IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2419

Phase II/III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma (BioFront Trial)
Research Committee(s)
Genitourinary Cancer
Activated
04/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase